Search
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Allergic reactivity to Isoeugenol may be identified with a patch test.
Esomeprazole
go.drugbank.com/drugs/DB00736ApprovedInvestigationalEsomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … [A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.
Categories: Antiinflammatory and Antirheumatic Products, Non-SteroidsProtriptyline
go.drugbank.com/drugs/DB00344ApprovedIn non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.
Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine, N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamineNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalReslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. … Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia [A31577]. Reslizumab was developed by Teva Pharmaceuticals.
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineFamtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalIt is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Aztreonam
go.drugbank.com/drugs/DB00355ApprovedInvestigationalIt is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.